Explore this article's sources with AI
Follow PeptideMethods on Google
Blood Pressure Events in GLP-1 Trials
A 32-trial meta-analysis found different hypertension and hypotension signals for tirzepatide and semaglutide, without a direct pooled head-to-head test.
Why we wrote this. Separate pooled safety signals can look like a direct drug comparison. We kept the review design and evidence limits visible.
In this article (5 sections)
A 2026 systematic review and meta-analysis pooled blood pressure-related adverse events from 32 randomized controlled trials involving 47,332 people with type 2 diabetes or obesity. In separate drug-specific analyses, tirzepatide was associated with fewer hypertension-related events but more hypotension-related events. Semaglutide was not associated with a statistically clear change in either event category[1].
This is a safety meta-analysis, not a trial that randomly assigned people to tirzepatide or semaglutide and made blood pressure events its primary head-to-head outcome. Its pooled risk ratios summarize comparisons inside the eligible trial evidence for each medicine. They should not be read as proof that tirzepatide has a stronger blood pressure effect than semaglutide for an individual patient.
What the review measured
The authors searched PubMed, Scopus, Web of Science, Embase, CENTRAL and ClinicalTrials.gov from inception through 26 September 2025. They included randomized controlled trials of tirzepatide or semaglutide used for type 2 diabetes or obesity, then pooled treatment-emergent adverse events related to hypertension and hypotension with a random-effects model[1]. A random-effects model allows the estimated treatment effect to vary across studies rather than assuming every trial measures one identical effect.
The endpoint matters. A hypertension-related adverse event is not the same measurement as the average change in systolic blood pressure, and a hypotension-related event is not a continuous cuff reading. Adverse-event counts depend on how each trial defined, detected and reported an event. The abstract does not provide the event definitions, absolute event counts or trial-by-trial denominators, so this article does not infer them.
The review is classified by PubMed as both a systematic review and a meta-analysis, not as a new clinical trial. Its record identifies 32 randomized trials and 47,332 participants, but it does not say that all participants contributed to every pooled endpoint[2]. That distinction prevents the total review population from being mistaken for the denominator of each risk ratio.
The pooled tirzepatide findings
For tirzepatide, the pooled risk ratio for hypertension-related events was 0.40, with a 95% confidence interval from 0.26 to 0.60. A risk ratio below 1 means fewer events were recorded in the tirzepatide groups than in their trial comparator groups. The interval did not cross 1, and the reported p value was below 0.001[1]. This is a relative result. Without the absolute event counts exposed in the abstract, it cannot tell readers how many additional or fewer people experienced an event.
The direction reversed for hypotension-related events. Tirzepatide was associated with a pooled risk ratio of 2.45, with a 95% confidence interval from 1.35 to 4.45 and a p value of 0.003. In a higher-dose subgroup, the risk ratio was 2.58, with a 95% confidence interval from 1.38 to 4.81[1]. The review authors describe this as a dose-related signal. The accessible abstract does not expose the dose cutoffs, absolute rates or subgroup interaction test, so it cannot support a dosing rule or a personalized forecast.
The pooled semaglutide findings
For semaglutide, neither pooled result met the review's threshold for a statistically clear association. The risk ratio was 0.81 for hypertension-related events, with a 95% confidence interval from 0.57 to 1.15. For hypotension-related events, it was 1.39, with an interval from 0.81 to 2.36. Both intervals crossed 1[1].
A result that is not statistically significant is not proof of no effect. The semaglutide estimates remain compatible with lower or higher event risk within their confidence intervals. The review abstract mentions possible protective signals in high-dose subgroups but does not expose enough detail to assess those analyses. We therefore do not treat that phrase as a settled finding.
Why this is not a direct drug comparison
One trial cited by the review did directly randomize 1,879 people with type 2 diabetes to three tirzepatide doses or semaglutide 1 mg for 40 weeks. Its primary endpoint was change in glycated hemoglobin, not a blood pressure event comparison. The accessible abstract reports glucose, body weight and common adverse events but does not report the hypertension and hypotension event counts used in the new synthesis[3].
The evidence base also contains trials with different populations and comparators. STEP 1, for example, randomized 1,961 adults with overweight or obesity without diabetes to semaglutide 2.4 mg or placebo for 68 weeks, with body weight as a coprimary endpoint[4]. Pooling adverse events across such programs can estimate a drug-specific signal, but it does not create one uniform tirzepatide-versus-semaglutide experiment.
The safest comparison is therefore within each pooled estimate: tirzepatide versus its eligible trial comparators, and semaglutide versus its eligible trial comparators. Comparing the two risk ratios against each other would require a valid between-drug analysis that accounts for study design, population, dose and comparator. The abstract does not report such an analysis.
What remains unknown
The publisher page exposes the abstract and reference list but identifies the article body as subscription content. PubMed and Europe PMC list no PMCID or open-access full text. We could not inspect the review's risk-of-bias judgments, heterogeneity estimates, absolute event tables, study-level exclusions or detailed subgroup methods. Those gaps limit how far the pooled numbers can be interpreted.
For someone prescribed either medicine, the practical point is not to choose a drug from these relative estimates. Blood pressure symptoms, other medicines and baseline cardiovascular risk need individual review. The broader evidence and approved-use context are covered in our tirzepatide overview and semaglutide overview. New dizziness, fainting or concerning blood pressure readings should be discussed with the clinician managing treatment rather than used to change a prescription independently.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Tirzepatide and semaglutide are prescription medicines. Treatment and monitoring decisions should be made with a qualified healthcare professional who knows the individual's history. PeptideMethods.com does not sell, distribute or facilitate the sale of any product.
Frequently asked
Did the meta-analysis compare tirzepatide directly with semaglutide?
Not as one pooled head-to-head blood pressure analysis. It reported separate drug-specific risk ratios across eligible randomized trials. Those estimates should not be ranked against each other as if every participant came from the same direct comparison.
What did the review find for tirzepatide?
Tirzepatide was associated with fewer hypertension-related events (RR 0.40, 95% CI 0.26 to 0.60) and more hypotension-related events (RR 2.45, 95% CI 1.35 to 4.45) versus trial comparators. The abstract did not provide absolute event rates.
What did the review find for semaglutide?
The pooled estimates did not show a statistically clear association with hypertension-related events (RR 0.81, 95% CI 0.57 to 1.15) or hypotension-related events (RR 1.39, 95% CI 0.81 to 2.36). That does not prove there is no effect.
Sources
- [1]Chen QX et al. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis. Endocrine. 2026;91(1):275. PMID 42603240.Tier 1 · primary↩
- [2]NCBI PubMed EFetch record for Chen QX et al., PMID 42603240 (abstract, publication types and record-level identifiers).Tier 1 · primary↩
- [3]Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021. PMID 34170647.Tier 1 · primary↩
- [4]Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. PMID 33567185.Tier 1 · primary↩
No revisions yet. First published .